First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
JAMA · 15.04.2025 · 333 (15) · 1305
DOI: 10.1001/jama.2024.28463 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 15.04.2025. Verfasst von Xiaotian Zhang und 20 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Resea…. Hauptthemen laut MEDLINE: Adenocarcinoma, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Stomach Neoplasms. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Importance Gastric cancer, including gastroesophageal junction cancer, is one of the most commonly diagnosed cancers worldwide, with high mortality. Sugemalimab is a fully human anti–programmed death-ligand 1 (PD-L1) antibody. The combination of sugemalimab and chemotherapy showed promising antitumor activity and safety in a phase 1b study among patients with treatment-naive, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. This combination was further evaluated in the GEMSTONE-303 phase 3 trial.
Objective
To evaluate the efficacy of sugemalimab in combination with capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX as first-line treatment for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with PD-L1 combined positive score (CPS) of 5 or greater. Design, Setting, and Participants GEMSTONE 303 is a phase 3, randomized, double-blind, placebo-controlled study conducted at 54 sites in China that enrolled patients from April 9, 2019, through December 29, 2021, with follow-up to July 9, 2023. A total of 479 eligible patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS of 5 or greater who did not receive any prior systemic therapy were randomized.
Intervention
Patients received sugemalimab (1200 mg intravenously) (n = 241) or placebo (n = 238) every 3 weeks for up to 24 months, plus CAPOX every 3 weeks for up to 6 cycles. Main outcomes and Measures Primary outcomes were overall survival and investigator-assessed progression-free survival.
Results
Baseline characteristics were well balanced between the 2 groups. Most patients were male (71.4% in sugemalimab group, 74.8% in placebo group). Median follow-up was 25.1 months in the sugemalimab group and 26.3 months in the placebo group. The sugemalimab group demonstrated significant improvements in overall survival (median, 15.6 months [95% CI, 13.3-17.8] vs 12.6 months [95% CI, 10.6-14.1]; hazard ratio, 0.75 [95% CI, 0.61-0.92]; P = .006) and progression-free survival (median, 7.6 months [95% CI, 6.4-7.9] vs 6.1 months [95% CI, 5.1-6.4]; hazard ratio, 0.66 [95% CI, 0.54-0.81]; P < .001). Grade 3 or higher treatment-related adverse events occurred in 53.9% of patients in the sugemalimab group and 50.6% in the placebo group. Conclusions and Relevance Sugemalimab plus chemotherapy significantly prolonged overall survival and progression-free survival with a manageable safety profile in previously untreated patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Trial Registration ClinicalTrials.gov Identifier: NCT03802591
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer…
- Gastroenterology Department, Henan Cancer Hospital, Zhengzhou, China.
- Cancer Chemotherapy Department, Anhui Provincial Hospital, Hefei, China.
- Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
- Oncology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Medical Oncology Department, Henan Provincial People's Hospital, Zhengzhou, China.
Zitieren
APA
Zhang, X., Wang, J., Wang, G., Zhang, Y., Fan, Q., Lu, C., Hu, C., Sun, M., Wan, Y., Sun, S., Wang, J., Zhang, L., Shu, Y., Luo, J., Zhu, D., Shen, Z., Yao, S., Shi, Q., Yang, J., …, & GEMSTONE-303 Investigators (2025). First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer. JAMA, 333(15), 1305. https://doi.org/10.1001/jama.2024.28463
Vancouver
Zhang X, Wang J, Wang G, Zhang Y, Fan Q, Lu C, et al. First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer. JAMA. 2025;333(15):1305. doi:10.1001/jama.2024.28463
BibTeX
@article{Zhang2025,
author = {Zhang, Xiaotian and Wang, Jufeng and Wang, Gang and Zhang, Yanqiao and Fan, Qingxia and Lu, Chuangxin and Hu, Changlu and Sun, Meili and Wan, Yiye and Sun, Sanyuan and Wang, Junye and Zhang, Li and Shu, Yongqian and Luo, Jie and Zhu, Dan and Shen, Zhenwei and Yao, Sheng and Shi, Qingmei and Yang, Jason and Shen, Lin and GEMSTONE-303 Investigators, GEMSTONE-303 Investigators},
title = {First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer},
journal = {JAMA},
year = {2025},
volume = {333},
number = {15},
pages = {1305},
doi = {10.1001/jama.2024.28463}
}
EUVIMED